Agile Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Agile Therapeutics, Inc.
Mid-sized M&A, collaborations, creative financing, and biotech consolidation will feature in 2023. IPOs and follow-ons play bit-parts.
Private Company Edition: While Coya Therapeutics raised $15.25m in the final initial public offering in the US last year, Apnimed stayed private raising $80m in a series C extension and Metagenomi extended its series B by $100m to total $275m.
Despite patient dissatisfaction, contraceptive options have made little advancement since the turn of the century – but a cohort of novel, non-hormonal products could see this all change.
National Resilience, Parker Institute team to incubate cancer startups. Metropolitan AntiViral Drug Accelerator will focus on eight molecular features of SARS-CoV-2 to create novel oral antivirals.
- Drug Delivery
- Controlled Release
Surgical Equipment & Devices
- Minimally or Less Invasive
- Surgical Equipment & Devices
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.